[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Addis Ababa University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":129},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,39,79,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100640213","effectiveness-and-implementation-of-the-dinknesh-digital-palliative-care-tool-in-ethiopia-100640213",false,"NCT07574281","Effectiveness and Implementation of the DINKNESH Digital Palliative Care Tool in Ethiopia","Effectiveness and Implementation Determinants of the DINKNESH App Compared to Paper-Based Assessment Tools for Palliative Care: A Mixed-Methods Cluster Randomized Trial in Addis Ababa, Ethiopia","Inclusion Criteria\n\n* For patients(Quantitative Part):\n\n  * Adults aged 18 years or older\n  * Currently diagnosed with one or more chronic conditions and receiving home-based follow-up care from a participating Family Health Team within the catchment area of a selected study cluster\n  * Willing to provide verbal informed consent, or has a primary caregiver willing to provide proxy consent\n* For healthcare workers:\n\n  * Staff members of the Family Health Team at the selected clusters\n  * Involved in delivering or supervising palliative care services during the study period\n  * For the qualitative part: Participated in the DINKNESH App implementation process and is willing to participate in a Focus Group Discussion (FGD)\n\nExclusion Criteria\n\n* For patients\n\n  * Patients whose clinical condition prevents both self-participation and proxy participation in the assessment process\n  * Patients already formally identified and referred for palliative care prior to the study period\n* For healthcare workers:\n\n  * Staff members planning to be absent for more than 1 day during the six-week active study period\n  * Healthworkers not present during the training session","ALL","18 Years",{"count":19,"type":20},1440,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to learn if a digital health app called DINKNESH is effective for palliative care identification compared to traditional paper-based assessment tools. It will also look at the factors that help or hinder the use of this app in primary care settings.\n\nThe main questions it aims to answer are:\n\nDoes the DINKNESH app improve palliative care assessments compared to paper forms?\n\nWhat are the main barriers and facilitators for Health Extension Workers when using the app in their daily work?\n\nWe will compare the DINKNESH app to standard paper-based tools to see if digital tools improve clinical assessment and implementation.\n\nParticipants will:\n\nBe assessed for palliative care needs using either the DINKNESH mobile app or standard paper forms.\n\nReceive routine follow-up care as determined by their health provider.\n\n(For health workers): Participate in interviews or surveys to discuss their experience using the assigned assessment tool.",[26],"Palliative Care","NOT_YET_RECRUITING","2026-05-04",{"date":30,"type":31},"2026-05-07","ACTUAL",{"date":33,"type":20},"2026-04",{"date":35,"type":20},"2026-05",{"name":37,"class":38},"Addis Ababa University","OTHER",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":47,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":51,"conditions":52,"keywords":59,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100624462","multicomponent-care-for-aromatase-inhibitor-related-musculoskeletal-symptoms-100624462","NCT07409948","Multicomponent Care for Aromatase Inhibitor-Related Musculoskeletal Symptoms","Clinical Effectiveness and Implementation Outcomes of a Multicomponent Intervention for Aromatase Inhibitor-Associated Musculoskeletal Symptoms: A Hybrid Type 1 Randomized Controlled Trial","AIMSS-CARE","Inclusion Criteria:\n\n1. Pathologically confirmed hormone receptor-positive (HR+) breast cancer.\n2. Aged 18 years or older.\n3. Currently receiving aromatase inhibitor therapy (e.g., anastrozole, letrozole, or exemestane) for at least 2 months.\n4. Experiencing aromatase inhibitor-induced musculoskeletal symptoms, defined as a worst joint pain score ≥ 2\u002F10 on the Brief Pain Inventory (BPI) during the past 7 days.\n5. Capable of understanding the study and willing to sign informed consent.\n\nExclusion Criteria:\n\n1. History of fracture or major surgery within the past 6 months.\n2. Patients diagnosed with arthritis (e.g., rheumatoid arthritis).\n3. Patients diagnosed with osteoporosis according to WHO criteria (T-score -2.5).\n4. Recurrent or metastatic breast cancer, or receipt of chemotherapy or radiotherapy during the study period.\n5. Presence of other primary malignancies.\n6. Patients with severe heart, brain, liver, or kidney dysfunction, or infectious diseases.\n7. Patients with severe mental, cognitive, or behavioral disorders that hinder understanding or participation in the study.","FEMALE",{"count":49,"type":20},88,[23],"Breast cancer patients who receive endocrine therapy particularly aromatase inhibitors often experience aromatase inhibitors associated symptoms (AIMSS) such as joint and muscle pain along with stiffness and fatigue that can disrupt with daily activities and lead some patients to stop treatment early. A structured intervention program named AIMSS-CARE (Aromatase Inhibitor-associated Musculoskeletal Symptoms-Comprehensive Adapted Rehabilitation Evaluation) developed in China that combines exercise, education, symptom monitoring, and follow-up has been shown to reduce these symptoms and improve treatment adherence.\n\nThis study will adapt this program for use in Ethiopia while testing its effectiveness to enhance pain management, treatment adherence and quality of life among Ethiopian breast cancer patients receiving endocrine therapy. The study will be conducted at Tikur Anbessa Specialized Hospital in Addis Ababa, Ethiopia.\n\nEighty-eight patients will be randomly assigned to either the adapted intervention program or usual care. The research will also examine the feasibility and acceptability of the intervention to patients and healthcare providers, and what factors influence its successful implementation. Results will help determine whether this program can be used more widely in Ethiopia and other African cancer centers.",[53,54,55,56,57,58],"Breast Neoplasms","Musculoskeletal Pain","Arthralgia","Musculoskeletal Diseases","Pain","Fatigue Syndrome, Chronic",[60,61,62,63,64,65,66,67,68,69,70],"Breast neoplasms","Aromatase inhibitors","endocrine therapy","Randomized controlled trial","pain","quality of life","fatigue","treatment adherence","musculoskeletal symptoms","symptom monitoring","exercise and rehabilitation","2026-02-07",{"date":73,"type":31},"2026-02-13",{"date":75,"type":20},"2026-03-15",{"date":77,"type":20},"2026-11",{"name":37,"class":38},{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":47,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":21,"phases":90,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},"100555685","key-interventions-to-improve-the-follow-up-adherence-post-cervical-precancerous-lesion-treatment-in-ethiopia-100555685","NCT06515301","Key Interventions to Improve the Follow-up Adherence Post Cervical Precancerous Lesion Treatment in Ethiopia","Key Interventions to Improve the Follow-up Adherence Post Cervical Precancerous Lesion Treatment in Ethiopia: A Pragmatic Randomized Controlled Trial","Inclusion Criteria:\n\n* Women aged 30-49 (HIV-negative).\n* Women over 25 (HIV-positive).\n* Treated for suspicious cervical lesions after a positive VIA screening.\n\nExclusion Criteria:\n\n* History of hysterectomy.\n* Diagnosis of other histological invasive cervical cancer.\n* Suspicious cervical cancer cases.\n* Pregnancy.\n* Prior screening history.\n* Vaginal bleeding.\n* Lack of consent.","25 Years","49 Years",{"count":89,"type":20},466,[23],"The goal of this pragmatic randomized control trial is to evaluate the effectiveness of three interventions in improving follow-up adherence among women treated for suspicious cervical lesions in primary healthcare settings in Ethiopia. The interventions include structured nurse-led telephone call reminders, home-visit reminders led by health extension workers, and application-based automated SMS text reminders. The main questions it aims to answer are:\n\n* Does structured nurse-led telephone call reminders improve follow-up adherence among women treated for suspicious cervical lesions compared to standard care?\n* Does home-reminder visits led by a Health Extension Worker (HEW) improve follow-up adherence among women treated for suspicious cervical lesions compared to standard care?\n* Does app-based automated SMS reminders improve follow-up adherence among women treated for suspicious cervical lesions compared to standard care?\n\nStructured Nurse-Led Telephone Call Reminders\n\n* Participants will receive proactive phone call reminders for scheduled follow-up visits.\n* The intervention includes three rounds: initially at 4 months post-recruitment, then every 4 months for HIV-negative women over a year, and every 2 months for 6 months for women living with HIV.\n\nHome-Reminder Visits Led by HEW Health Extension Workers (HEWs) will conduct door-to-door visits to remind participants of their scheduled follow-up appointments.\n\n• Door-to-door Visits will occur initially at 4 months (for HIV-negative women) and 2 months (for HIV-positive women) post-recruitment, then every 2 months for 6 months for HIV-positive and every 4 months for 12 months for HIV-negative participants.\n\nApp-Based Automated SMS Reminders\n\n* Participants will receive SMS-based reminders for their follow-up visits.\n* The intervention consists of three rounds: initial texts at 4 months and 2 months post-recruitment for HIV-negative and HIV-positive women, respectively, followed by reminders every 2 months for 6 months for HIV-positive women and every 4 months for 12 months for HIV-negative women.",[93],"Suspicious Cervical Cancer Lesions Follow up Adherence","RECRUITING","2025-06-05",{"date":97,"type":31},"2025-06-10",{"date":99,"type":31},"2024-11-20",{"date":101,"type":20},"2025-12-30",{"name":37,"class":38},1,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":47,"minAge":17,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":21,"phases":114,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":128,"locationsCount":103},"100512058","concomitant-curcumin-palliative-radiotherapy-in-advanced-cervical-cancer-trial-100512058","NCT05947513","Concomitant Curcumin Palliative Radiotherapy in Advanced Cervical Cancer Trial","Feasibility, Safety, and Efficacy of Concomitant Curcumin in Patients Undergoing Palliative Radiotherapy for FIGO Stage IIIB-IVA Cervical Cancer: An Open-label Pilot Trial","CuPRAC","Inclusion criteria:\n\n* Age \\>18 years old (Adult, Older Adult)\n* Histologically confirmed squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix, FIGO stage IIIB-IVA\n* Undergoing for standard of care palliative radiotherapy without chemotherapy as per the local treatment guideline\n* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, 2\n* Adequate liver function (aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x ULN (Upper Limit of Normal); total serum bilirubin ≤1.5 x ULN); blood cell counts (absolute neutrophils count ≥1.500\u002Fmm3; platelet count ≥100.000\u002Fmm3; hemoglobin ≥10.0 g\u002FdL); renal function (serum creatinine ≤1.5 x ULN; estimate creatinine clearance (Cockcroft-Gault) ≥60 mL\u002Fmin)\n* Participants must have measureable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) V1.1.\n* Agree to use an effective form of contraception (e.g., true abstinence (not periodic abstinence), barrier contraception, highly effective hormonal contraception) if the participant is of child bearing age\n* Give informed consent\n\nExclusion criteria:\n\n* Cervical cancer patients who are candidates for single dose palliative radiotherapy\n* Patients with severe or bilateral hydronephrosis\n* Evidence of distant metastases\n* Receiving any other investigational agent concurrently or within the last 4 weeks before enrollment\n* Received any previous radiation or chemotherapy for cervical cancer\n* Underwent surgery in the four weeks prior to the enrolment date or scheduled to undergo surgery within eight weeks after end of treatment\n* Currently using of any chemotherapy or scheduled to receive within eight weeks after end of treatment\n* Known allergy to turmeric or its derivatives (ginger, curry, cumin, or cardamom)\n* Known allergy to fenugreek, peanut, soy, lentil, pea, bean, and chickpea\n* Presence of conditions that precludes the safe administration of the trial intervention and\u002For prohibit adequate compliance to study requirements including chronic ongoing infections (like HIV, Hepatitis B or C), uncontrolled hypertension, heart failure, cardiac arrhythmia, unstable angina, chronic obstructive lung disease, diabetes mellitus, chronic renal disease, chronic liver disease, biliary tract obstruction or cholelithiasis, gastric or duodenal ulcers, autoimmune or inflammatory disorders, a coagulation or platelet disorder, seizure disorders and psychiatric illness. Patients with disorders other than the ones specified above may also be excluded based on the judgment of the principal investigator.\n* Pregnant and breastfeeding women\n* Participants with circumstances that will not permit completion of the study or required follow-up. For instance, if travel to and from treatment site is an issue.",{"count":113,"type":20},27,[23],"The goal of this clinical trial is to test curcumin as an adjunct treatment in patients with cervical cancer receiving standard-of-care palliative radiation. The main questions it aims to answer are:\n\n1. Is adding curcumin to standard-of-care palliative radiotherapy of cervical cancer patients feasible? Is conducting this study feasible?\n2. Does adding curcumin to standard-of-care palliative radiotherapy of cervical cancer patients improve therapeutic responses?\n3. Is adding curcumin to standard-of-care palliative radiotherapy of cervical cancer patients safe?\n4. How much curcumin is absorbed into the body and how long will it stay in the body?\n\nParticipants will:\n\ni. Take 250 mg curcumin capsules four times per day for 4-6 weeks in addition to the prescribed palliative radiotherapy.\n\nii. Provide blood and urine samples for laboratory tests. iii. Provide blood samples to measure curcumin levels in their body. iv. Obtain CT-scan to measure their tumor response. v. Complete questioners to measure improvements to their quality of life, if any.",[117],"Cervical Cancer",[119,120,121],"Curcumin","Cervical cancer","Radiosensitizer","2025-04-16",{"date":124,"type":31},"2025-04-20",{"date":126,"type":31},"2025-04-10",{"date":33,"type":20},{"name":37,"class":38},""]